Q4 2025 Earnings Call February 12, 2026 4:30 PM ESTCompany ParticipantsSean Christensen - Vice President of Finance and ...

Credence Research Inc. has released a new study on the Blood Glucose Monitoring Devices Market. According the report the ...

As GLP-1 use rise, constipation remains a leading cause of discontinuation. Experts offer practical strategies for prevention and management.

Meditation isn’t thinking about nothing. New research reinforces that it’s a mind-altering, dynamic state that promotes focus ...

According to preliminary data, the S&P 500 gained 2.32 points, or 0.03 per cent, to end at 6,835.08 points, while the Nasdaq Composite lost 52.04 points, or 0.2 per cent, to 22,545.11. The Dow Jones ...

Jacob Steven Leach, DexCom, Inc.'s President and CEO who will summarize our recent highlights and ongoing strategic initiatives. Please note that there are also slides available related to our fourth ...

DexCom expects 2026 total revenue to be in a range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year. Sylvain indicated, "This guidance assumes continued strong ...

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish ...

DexCom (NASDAQ: DXCM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, ...

DexCom Inc. DXCM shares were mostly flat in Thursday's extended trading after the company released its fourth-quarter earnings report. Here's a look at the details in the report. Watch the price DXCM ...

New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.